Please login to the form below

Cytokinetics

This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.

Trial of Amgen, Servier’s heart failure drug clears interim check

Originally developed by Cytokinetics, omecamtiv mecarbil is the first in a new class of drugs – dubbed cardiac myosin activators – that are designed to increase the duration of cardiac muscle contractility and

Latest news

Amgen, Servier heart failure drug clears trial hurdle

Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs called cardiac myosin activators, that are designed to increase the duration of cardiac muscle contractility and improve ... Amgen recently started phase 1 trials of
Amgen, Servier start second phase 3 trial of heart failure hope

Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance in heart failure. ... Amgen, Servier and Cytokinetics are
Roche reshuffles its executive committee, again

Prior to joining Genetech Sabry was chief executive officer for start-up biotech and was founder and chief executive of biopharma Cytokinetics.
Amgen agrees to take Cytokinetics' heart failure drug into phase III

originator, Cytokinetics, which has been waiting for the big biotech to make a decision for several weeks. ... Cytokinetics said recently that meetings have been held with both the FDA and EMA to discuss the design of the outcomes study, which is due to
Biogen buys into Ionis' nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months”

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
Deal Watch July 2016

Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and
Astellas: Ten years young

option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.
Heart failure therapy embarks on a new era

In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
Deal Watch table for December 2014

Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....